(TKI) for other abnormalities, e.g., ruxolitinib and sorafinib for cases with JAK2 or FLT3 fusions, respectively [8, 9] .
Some cases of HE show clinical responses to imatinib despite no evidence of a recognized underlying abnormality in an imatinib-sensitive fusion gene [10] . For many of these cases, the responses are transient [5] , but occasional longer-term responders have been reported [7] . Recently, it has been suggested that a somatically acquired KIT variant c.1621 A>C; p.Met541Leu (hereafter referred to as KIT M541L) is associated with imatinib response in HE patients negative for PDGFRA/B rearrangements [11] . Whilst this finding is supported by the fact that M541L has been reported to increase the sensitivity of the KIT receptor to stem cell factor [12] , it remains controversial because this variant is a recognized inherited single-nucleotide polymorphism (rs3822214), with a minor allele frequency of 0.08 in the ExAC database (http://exac.broadinstitute.org/), and it is classified as benign/likely benign on ClinVar (www.ncbi.nlm.nih.gov/ clinvar/). Nevertheless, it has been suggested that HES patients should be screened for KIT M541L, as positive cases may benefit from imatinib treatment [11] .
To evaluate the significance of KIT M541L in HE, we aimed to (i) compare the KIT M541L allele frequency beHypereosinophilia (HE), defined as peripheral blood eosinophil counts of persistently >1.5 × 10 9 /L [1] , is seen in a wide range of reactive and clonal disorders. In hypereosinophilic syndrome (HES), HE results in potentially life-threatening organ damage as a consequence of eosinophilic tissue infiltration and/or the release of toxic granule proteins [2] . The underlying causes of HE are complex, heterogeneous, and incompletely understood, but an important subset is characterized by clonal HE driven by underlying acute or chronic myeloid or lymphoid neoplasms [2, 3] .
Clonal HE is frequently associated with somatic mutations that result in the constitutive activation of specific tyrosine kinases (TK), in particular, PDGFRα, PDGFRβ, FGFR1, ABL, JAK2, or FLT3 [2] . Most commonly, translocations or other genomic rearrangements generate TK fusion genes, e.g., FIP1L1-PDGFRA, ETV6-PDGFRB, ZMYM2-FGFR1, PCM1-JAK2, and many others [2] , but some cases test positive for activating TK point mutations such as KIT D816V or JAK2 V617F [4] . Identifying driver fusion genes is critical for clinical management, e.g., patients with PDGFRA or PDGFRB rearrangements have excellent responses to imatinib, with most cases achieving sustained hematological and molecular remission [5] [6] [7] . Clinical benefit has also been achieved with TK inhibitors The absence of KIT M541L ARMS in 3 PDGFRA/B-negative HES patients who responded to imatinib. A tetra-primer ARMS assay was designed (http://primer1.soton.ac.uk/primer1.html), with inner primers designed to specifically amplify the normal and mutant KIT M541L sequences and outer primers to produce a positive control band for each reaction. Inner primers included mismatches to maximize allele discrimination (in lower case) and wild-type/ mutant specific bases (underlined). PCR primers were: forward outer (FO), 5′-GTACAATGTAACCAAGGTGAAGCTCTGA-3′; reverse outer (RO), 5′-ACAACCTTCCACTGTACTTCATA-CATGG-3′; forward wild-type-specific (Fwt), 5′-TAGCTGGCATGATGTGCATTATTGcGA-3′; reverse mutant-specific (Rmt), 5′-ACCTGTAAATATTTGTAGGTCAGAATtAG-3′. FO, RO, and Rwt primers were all used at a final concentration of 0.5 μM, and Rmt was used at 1 μM in PCR reactions using AmpliTaq Gold DNA polymerase, 25 ng genomic DNA, an annealing temperature of 60 ° C, and 35 cycles. Each product was a different size that could be clearly resolved on a 3% agarose gel stained with ethidium bromide. Reactions were prepared with 117 ng sonicated genomic DNA, 0.25 μM of each probe, 0.9 μM of each primer and "no dUTP" supermix (Bio-Rad, Watford, UK). Droplets were prepared using a QX200 droplet generator (Bio-Rad). Amplification was performed with an annealing temperature of 58 ° C for 40 cycles and droplets were measured using a QX200 droplet reader (Bio-Rad). Each sample was run in triplicate, with KIT M541L-positive, KIT M541L-negative, and no-template controls for each run. The percentage VAF was calculated by dividing the concentration of KIT M541L mutant droplets by the total concentration and multiplying by 100. Only samples with an accepted droplet number of >10,000 were included, as lower droplet numbers may produce less reliable results. The plots show the median, range, and interquartile range.
tween patients referred for the investigation of HE and normal healthy controls, (ii) investigate the variant allele frequency (VAF) in positive HE cases, to determine if KIT M541L mutations may be acquired somatically, and (iii) investigate the KIT M541L status in cases negative for PDGFRA/B rearrangements that responded to imatinib. We screened the healthy controls (n = 214) and the patients referred for the investigation of FIP1L1-PDG-FRA-negative HE (n = 220) for KIT M541L, using an amplification refractory mutation system (ARMS) PCR designed to amplify allele-specific products of different sizes and able to detect KIT M541L down to 5% VAF (Fig. 1a) . Forty-two (19%) of the HE cases tested positive for KIT M541L compared to 38 (18%) healthy controls. The allele frequency between the control and HE groups was indistinguishable (0.095 vs. 0.098; p = 0.91; the Fisher exact two-tailed test). Digital droplet PCR was used for patients heterozygous for KIT M541L in the ARMS assay to determine whether the variant burden was close to 50% (consistent with a constitutional polymorphism) or significantly <50% (suggestive of a somatic mutation). Of the 42 KIT M541L heterozygous HE cases, 40 had sufficient DNA for analysis. The median allele burden was 50.2% (range 47.9-56.0%), indistinguishable from that in healthy controls (n = 28), and thus consistent with all instances of KIT M541L in HE being constitutional (Fig. 2) .
Finally, we studied pretreatment DNA from 3 patients with HES negative for PDGFRA/B rearrangements, who were treated with imatinib (400 mg/day) and showed a normalization of eosinophil count at a median of 0.8 months (range 0.4-5.0 months) after treatment for a duration of 13.6 months (range 3.7-44.8 months). None of the 3 imatinib responders tested positive for KIT M541L prior to treatment (Fig. 1b) .
In conclusion, we found (i) no increased prevalence of KIT M541L in HE patients compared to controls, (ii) no case where KIT M541L was acquired somatically, and (iii) that this variant was not present in 3 HES patients who responded to imatinib. Whilst we cannot exclude the possibility that KIT M541L may be acquired somatically in very rare cases, we conclude that there is no clinical value in screening for this variant on a routine basis in patients with HE or HES.
